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The emerging role of retromer in neuroprotection
Kirsty J McMillan1, Hendrick C Korswagen2 and Peter J Cullen1
Efficient sorting and transportation of integral membrane
proteins, such as ion channels, nutrient transporters, signalling
receptors, cell–cell and cell–matrix adhesion molecules is
essential for the function of cellular organelles and hence
organism development and physiology. Retromer is a master
controller of integral membrane protein sorting and transport
through one of the major sorting station within eukaryotic cells,
the endosomal network. Subtle de-regulation of retromer is an
emerging theme in the pathoetiology of Parkinson’s disease.
Here we summarise recent advances in defining the
neuroprotective role of retromer and how its de-regulation may
contribute to Parkinson’s disease by interfering with: lysosomal
health and protein degradation, association with accessory
proteins including the WASH complex and mitochondrial
health.
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Introduction
The endosomal network comprises an inter-connected
series of intracellular membrane-bound compartments
that are present within all eukaryotic cells [1,2]. This
‘supra-organelle’ serves an essential function in control-
ling the transport of integral membrane proteins and
associated proteins and lipids (together termed ‘cargos’)
to a variety of cellular compartments, a function that is
vital for development as well as cellular and organismal
level physiology [3] (Figure 1).
Cargo can enter the network from the plasma membrane,
the biosynthetic pathway and various other routes that
include the autophagic pathway [1,2]. Once within the
network cargos have essentially two fates: they are either
sorted towards the lysosome for degradation or are
retrieved from this fate for recycling. Cargo can be
recycled to the cell surface, the biosynthetic pathway
(at the level of the trans-Golgi network (TGN)) and other
organelles that include autophagosomes and lysosome-
related organelles (Figure 2) [1,2]. While we have an
advanced understanding of the molecular mechanisms
that govern cargo sorting for degradation [4], relatively
little is known about the corresponding details of cargo
retrieval and recycling [5]. That said, the identification of
retromer as one of the evolutionary conserved conductors
for orchestrating endosomal cargo retrieval and recycling
has begun to shed light on these complex events [2,6]. In
so doing, exciting and new emphasis has been placed on
the importance of cargo retrieval and recycling in neuro-
protection and age-related neurodegenerative disease [7].
Here we review some of the most recent literature explor-
ing retromer’s role in this context, with a specific focus on
Parkinson’s disease (PD), and consider the future direc-
tion of this emerging research area.
Retromer and Parkinson’s disease
Retromer is an ancient and highly conserved heterotri-
meric protein complex, consisting of VPS35, VPS29 and
VPS26 (two isoforms, A and B, in humans), and its
activity is vital for regulating the retrieval and recycling
of numerous cargos away from the degradative pathway
for delivery to the TGN, the cell surface as well as
specialised organelles [2,6,8]. Reflecting its central
importance, retromer is essential for development [9]
and an increasing body of evidence is consistent with
retromer serving a neuroprotective role (especially in
age-related neuronal health). Furthermore, disruption of
retromer has been observed in a number of diseases
including PD [7].
PD is the second most common neurodegenerative dis-
order after Alzheimer’s disease (AD) and affects approxi-
mately 1.5% of the population over the age of 65. It is
characterised by several motor impairments including
tremor, rigidity, akinesia and postural instability, which
are known to stem from the progressive loss of dopami-
nergic neurons within the substantia nigra pars compacta
(SNpc) [10,11]. However, PD is now known to be a
multifactorial disorder in that other cell types are affected
and symptoms range from depression and cognitive
decline to gastrointestinal problems [12]. Understanding
the molecular pathways affected in PD is crucial in
understanding the pathoetiology of this disease and the
exploration of rationale routes for therapeutic
intervention.
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Retromer was first highlighted in the pathogenesis of PD
through the discovery of the VPS35(p.D620N) mutation
[8,9]. While at low frequency, this mutation has been
observed in a number of patients with familial as well as
sporadic PD and leads to an autosomal dominant late
onset form of the disease [13,14]. Several other rare
nonsynonymous mutations have also now been identified
within retromer including VPS26A (p.K93E, p.M112V
and p.K297X), VPS29 (p.N72H) and several in VPS35
including (p.G51S, p.P316A, p.R524W and p.L774M)
(Table 1) [13–20]. For those mutations that have been
analysed assembly of the retromer complex and its endo-
somal localisation are generally unperturbed, indicating
that these mutations do not cause a catastrophic traffick-
ing defect, consistent with the patients having a late onset
of disease [13–16,21,22].
Whilst the pathogenicity of these new mutations is as of
yet unclear they all point towards retromer, and more
broadly the process of endosomal cargo retrieval and
recycling, as having an important role in the development
of PD. Consistent with this, retromer has been shown to
be neuroprotective against the pathology of PD. Over-
expression of retromer has been shown to rescue against
LRRK2 mutant phenotypes in vitro and in Drosophila
models [23,24]. In addition, VPS35 is protective against
the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) as well as the pesticide rotenone both of which,
induce Parkinsonian phenotypes [24,25]. VPS35 hetero-
zygote mice (VPS35+/) exhibit dopaminergic neuron
loss and an increase in alpha synuclein expression, whilst
mice expressing a deletion of VPS35 specifically in their
dopaminergic neurons have a stronger phenotype display-
ing an enhanced reduction of dopaminergic neurons,
increased alpha synuclein expression and motor deficits,
all hallmarks of PD [25]. Additionally, VPS35 mRNA
levels are decreased in the SNpc of patients with PD
further emphasising an important role for retromer in the
pathogenesis of not only familial forms of the disease but
also sporadic PD [23]. However, overexpression of VPS35
has also been shown to be toxic in primary cortical
neurons and in a rat model, suggesting that the level of
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Retromer and Parkinson’s disease.
Retromer has been shown to play an important role in the pathology of Parkinson’s disease (PD). The different pathways shown to be affected by
retromer dysfunction are illustrated and include changes in lysosomal health and protein degradation, association with accessory proteins
including the WASH complex and mitochondrial health. MDV, mitochondria derived vesicles, CMA, chaperone mediated autophagy.
www.sciencedirect.com Current Opinion in Cell Biology 2017, 47:72–82
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Overview of the endosomal pathways implicated in Parkinson’s disease.
In physiological conditions cargo proteins enter the endosomal network where they are either retrieved and recycled (to the plasma membrane
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retromer expression is important and is likely to be highly
controlled and regulated [26].
The precise mechanism(s) by which retromer may be
involved in the pathology of PD remains unclear. PD has
been shown to cause defects in various molecular path-
ways including lysosomal health, autophagy, synaptic
activity and mitochondrial health [27]. In the following
we discuss the evidence linking retromer dysfunction to
each of these pathways.
The retromer-lysosomal degradation axis in
Parkinson’s disease
Retromer was initially discovered as a protein complex
required for sorting of cargo from the endosome back to
the TGN [28]. One classic retromer cargo is the cation-
independent mannose 6-phosphate receptor (CI-MPR).
This receptor is responsible for the trafficking of newly
synthesised hydrolases, such as cathepsin D, from the
TGN to the endosomal network and hence ultimately
their delivery to the lysosome [29,30]. Retromer retrieves
the unliganded CI-MPR from endosomes back to the
TGN, an essential event in maintaining iterative rounds
of CI-MPR and hydrolase trafficking [2]. Interestingly,
one substrate for cathepsin D mediated lysosomal degra-
dation is alpha-synuclein, a protein prevalent in Lewy
bodies, which is another hallmark of PD [31–33].
Disruption of lysosomal health has been shown to induce
accumulation and aggregation of alpha synuclein
highlighting this pathway as having an important role
in the degradation of alpha synuclein and thereby the
pathology of PD [34]. Alpha synuclein has been shown to
enter the lysosome via macroautophagy and chaperone-
mediated autophagy, both of which are also affected by
retromer suppression (see below) [34,35,36]. One idea
that is gaining attention is that retromer dysfunction
causes a reduction in the iterative rounds of CI-MPR
and hydrolase trafficking leading to a decrease in the
efficiency of hydrolase delivery to the lysosome. This
would result in lowered lysosomal activity due to a
decrease in the hydrolase content in the lysosome poten-
tially leading to the accumulation of non-degraded aggre-
gated proteins (such as alpha synuclein) and de-regulated
organelles. Indeed, in vitro and in vivo suppression of
retromer has been shown to affect CI-MPR trafficking
leading to abnormal cathepsin D processing and an
increase in alpha-synuclein levels [37]. On the flip side,
overexpression of VPS35 has been found to be protective
against the accumulation and aggregation of alpha-synu-
clein observed in a synucleinopathy transgenic mouse
model as well as in an alpha-synuclein prion-like seeding
mouse model [38]. This has been suggested to be due to
an increase in the trafficking of relevant hydrolases to the
lysosome for efficient protein degradation.
Two VPS35 mutations, p.D620N and p.R524W, have also
been shown to impair CI-MPR trafficking and result in
dysfunctional cathepsin D processing in vitro
[22,39,40]. In a neuroblastoma cell line this correlates
with an increase in alpha-synuclein aggregation, which is
consistent with a defect in protein degradation [22]. With
the mannose 6 phosphate (M6P) receptors, including the
CI-MPR, estimated to be important for the sorting of over
60 different hydrolases it is not difficult to comprehend
why dysfunction of retromer-mediated CI-MPR traffick-
ing may lead to a decrease in lysosomal health resulting in
impairment of protein degradation [41,42].
In addition to the M6P receptors two alternative receptors
have also been found to have a role in the trafficking of
enzymes and proteins to the lysosome: the lysosomal
integral membrane protein (LIMP-2) and sortilin [43].
CI-MPR has been shown to associate with LIMP-2 which
is responsible for targeting the enzyme b-glucocerebro-
sidase (b-Gcase) to the lysosome [42]. Mutations within
the glucocerebrosidase gene (GBA) cause an enzyme
deficiency that leads to the lysosomal storage disorder,
Gaucher’s disease. Interestingly, individuals carrying a
GBA mutation have a greater risk of developing PD,
further suggesting an important role for lysosome de-
regulation in PD [44,45]. Sortilin is linked to various
disorders including AD and interestingly, has also been
shown to interact with retromer suggesting an additional
role for retromer in lysosomal-enzyme trafficking in other
neurodegenerative disorders [46].
Another study found that expressing the
VPS35(p.D620N) mutation in vitro had no effect on
CI-MPR trafficking but they did report defects in
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(Figure 2 Legend Continued) (PM), trans-golgi network (TGN) or to specialised organelles) or sorted for degradation within the lysosome.
Retromer is involved in the retrieval and recycling of cargo away from the degradative pathway. Retromer dysfunction has been implicated in
Parkinson’s disease (PD). Several mechanisms are proposed including perturbations in lysosomal health, autophagy flux, mitochondria quality
control and the cell surface proteome. Impairment of retromer affects sorting of integral cell surface proteins, which can affect many aspects of
plasma membrane function. Furthermore, retromer dysfunction affects trafficking of hydrolases from the TGN to the lysosome (via CI-MPR)
affecting the health of the lysosome and resulting in reduced protein degradation. Retromer is also involved in the trafficking of proteins needed in
autophagasome formation, chaperone mediated autophagy (CMA) and mitochondria derived vesicles (MDV) all of which are involved in
maintaining proteostasis. Impairment of these different pathways are thought to lead to increases in alpha synuclein, the key protein present in
Lewy bodies in Parkinson’s disease, as well as other proteins and damaged organelles potentially leading to cell death. In addition, retromer
dysfunction has been shown to affect mitochondrial health due to changes in the expression of fission and fusion proteins which may also play a
role in the pathology of Parkinson’s disease. EE, early endosome; LE, late endosome, MT, mitochondria.
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autophagosome formation and the miss-trafficking of the
autophagy protein ATG9A [35] highlighting that other
protein degradation pathways may also be affected by
retromer. Consistent with this, the lysosome-associated
membrane glycoprotein 2a (Lamp2a) is another protein
that relies on endosomal retrieval by retromer for its
recycling to the TGN. Lamp2a is a receptor for chaper-
one-mediated autophagy (CMA), which is thought to
assist in the lysosomal-mediated degradation of alpha-
synuclein [47,48]. Suppression of retromer or expression
of the VPS35(p.D620N) mutation increases the degrada-
tion of Lamp2a leading to an increase in alpha-synuclein
expression [36]. Indeed, re-expression of Lamp2a into
VPS35 deficient dopaminergic neurons prevents alpha-
synuclein accumulation, consistent with an important role
for CMA and retromer in alpha-synuclein degradation
[36].
Overall, the role of retromer in maintaining lysosomal
health and the importance that this plays in the efficient
degradation of proteins, protein aggregates and de-regu-
lated organelles (via both the endosomal and autophagic
pathways) is an emerging theme in the neuroprotective
role of retromer (Figure 2).
The retromer-WASH axis in Parkinson’s
disease
To date the primary defect connected with the PD
associated VPS35(p.D620N) mutation is a twofold
decrease in the affinity of binding between VPS35 and
the FAM21 component of the pentameric WASH
complex [35,39]. This ancient complex, which in
addition to FAM21 contains WASH, SWIP, CCDC53,
and strumpellin (a protein that is itself associated with the
neurodegenerative movement disorder, hereditary spas-
tic paraplegia), mediates the Arp2/3-dependent nucle-
ation of actin filaments [49–51]. This is essential in the
organisation of functional F-actin subdomains on endo-
somes, and is required for efficient retromer-dependent
and retromer-independent retrieval and recycling of cargo
[49]. Interestingly, a mutation in one of a number of
WASH accessory proteins, namely DNAJC13 (a.k.a.
RME8), has also been linked to familial forms of PD
[52,53], providing evidence for the importance of the
retromer-WASH axis in this disease.
Functionally, the suppression of WASH affects the endo-
somal sorting of the CI-MPR and, as discussed above,
perturbed sorting of this receptor is observed with the
VPS35(p.D620N) mutation [39,40,49]. The WASH
complex is also involved in autophagasome formation
[54,55] and the trafficking of ATG9A suggesting that
the autophagy defects observed in VPS35(p.D620N) cells
are due, in part, to a decrease in endosomal recruitment of
the WASH complex [35]. The retromer-mediated
retrieval and recycling of cargo proteins back to the cell
surface also requires the WASH complex [56,57]. Mis-
localisation of the glucose transporter-1 (GLUT-1) in
cells expressing VPS35(p.D620N) has been reported
which, is consistent with a defect in retromer-mediated
endosome to cell surface sorting of this cargo protein
[35]. In support of this, the trafficking of the cell surface
protein dopamine receptor-1 is affected by the
VPS35(p.D620N) mutation in mouse dopaminergic
76 Cell organelles
Table 1
Summary of clinical features of patients with retromer mutations
Gene NT change AA change No. of patients Age AAO Initial symptom Clinical diagnosis
VPS35 c.G1858A p.D620N Various 47–54 Average
51.4
RESTING TREMOR PD
c.C2320A p.L774Ma 2 58/82 51/73 RESTING TREMOR PD
c.A1819G p.M607V 1 80 76 N/A PD
c.A1796G p.H599R 1 72 54 N/A PD
c.T1679C p.I560Ta 1 75 68 N/A PD
c.C1570T p.R524W 1 46 37 MICROGRAPHIA PD
c.C946T p.P316Sa 2 N/A 52/54 N/A PD
c.T723G p.I241M 1 74 72 POSTURAL TREMOR PD
c.G171A p.M57I 1 75 62 RESTING TREMOR PD
c.G151S p.G51Sa 2 61/76 57/64 TREMOR DPD/PD
c.A96T p.R32S 1 N/A N/A N/A PD
VPS26A c.A889T p.K297X 1 90 70 BRADYKINESIA DPD
c.A334G p.M112V 1 73 51 FREEZING GAIT PSP
c.A277G p.K93E 2 72/76 58/56 POSTURAL INSTABILITY/N/A MSA/PD
c.G380A p.R127Ha 1 78 70 BRADYKINESIA DPD
c.a922g p.N308Da 1 77 73 RIGIDITY PSP
VPS29 c.A216C P.N72Ha 1 82 70 NA PD
NT, nucleotide; AA, amino acid; No, number; AAO, age at onset; N/A, not applicable; PD, Parkinson’s disease; DPD, dementia with Parkinson’s
disease; PSP, progressive supranuclear palsy; MSA, multiple system atrophy.
a Either found in a control or unaffected family member [13–20].
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neurons resulting in abnormal dopamine signalling [58].
VPS35(p.D620N) knock-in mice also display impaired
dopaminergic neurotransmission in the striatum suggest-
ing a defect in the activity of dopaminergic neurons [59].
In addition, retromer has also been shown to be involved
in the trafficking of wntless, a receptor essential for WNT
secretion which has also been shown to be involved in
dopaminergic neuronal health and PD [60].
AMPA receptor recycling has also been shown to be
affected by the VPS35(p.D620N) mutation in rat primary
neuronal cultures and in dopaminergic cells derived from
patients carrying the p.D620N mutation supporting the
idea that changes in the cell surface proteome may play an
important role in protecting the cell from degeneration
[61]. Studies in yeast have also shown that the VPS35(p.
D620N) mutation increases the sensitivity to copper,
which has been suggested to be due to the miss-traffick-
ing of copper transporters [62]. Indeed, in human cells
endosomal retrieval and recycling of the copper trans-
porter ATP7A is retromer dependent [63]. There is
evidence that alterations in copper homeostasis play a
role in PD with excess copper leading to neuronal cell
death and alpha-synuclein aggregation [64], and so it will
be important to consider further the link between retro-
mer and copper homeostasis.
Recently, the VPS26A(p.K297X) mutation has been
shown to affect the retromer-WASH mediated endosomal
sorting of GLUT-1 through a reduced binding to the
cargo adaptor sorting nexin 27 (SNX27) [21,65]. SNX27
contains an amino terminal PDZ domain that associates
with cargo proteins containing a Type I PDZ domain-
binding motif (PDZbm) at their very carboxy-terminus
(the PDZbm in GLUT-1 being DSQV) [63,66,67].
Association of SNX27 with VPS26 (and hence the retro-
mer) is via an exposed b-hairpin in the SNX27 PDZ
domain that binds to a groove within the arrestin-like
structure of VPS26A [68]. Association to VPS26A
increases the affinity of SNX27 for its cargo by over
10-fold revealing an allosteric relationship between retro-
mer, SNX27 and cargo recognition [68]. As for cargo
recognition, the optimal amino acid sequences of the
PDZbm for high affinity binding to SNX27 have been
determined [66]. Using these sequence motifs coupled
with bioinformatics analysis, it has been determined that
the human genome encodes in excess of 400 proteins that
are likely cargos for SNX27-retromer mediated endoso-
mal sorting [66], over a hundred of which have been
validated [63]. If one combines these data, it is clear that
by sorting functional diverse cargos that include ion
channels, nutrient transports, and signalling receptors,
the SNX27-retromer-WASH axis plays an important role
in synaptic plasticity, nutrient uptake and metabolism,
development and signal transduction [63,66,69]. Such a
pleiotropic role is entirely consistent with the complex
phenotype observed in SNX27 null mice [70] and
provides insight into functional effects of reduced
SNX27 expression that has been observed in AD, Down’s
syndrome and infantile myoclonic epilepsy [71–73].
Interestingly in the context of cognition, SNX27 regu-
lates the endosomal retrieval and recycling of AMPA and
NMDA receptors, with loss of SNX27 leading to effects
on excitatory transmission, synaptic function and long
term potentiation [70,71,74,75]. Together these studies
suggest that disruption of retromer, or its accessory
proteins including SNX27 and the WASH complex,
can lead to a perturbed steady-state and activity-depen-
dent level of cell surface cargos, leading to perturbed
neuronal activity and potentially neuronal viability
(Figure 2).
The retromer-mitochondria axis in
Parkinson’s disease
Retromer has been suggested to have a role in mitochon-
drial health as VPS35 is protective against the neurotoxin
MPTP [21]. MPTP converts to MPP+, which by inhibit-
ing complex I of the mitochondrial respiratory chain leads
to cell death in the dopaminergic neurons of the SNpc
[25,76,77]. The mechanism(s) by which retromer is
involved in mitochondrial dysfunction however, is cur-
rently unclear. VPS35 is argued to localise within sub-
domains of the mitochondria and has been shown to
regulate the trafficking and degradation of MUL1
(MAPL), an E3 ubiquitin ligase enriched in mitochon-
dria-derived vesicles [78]. Mitochondria-derived vesicles
are thought to be involved in the transport of cargo from
the mitochondria to the peroxisome/lysosome for
degradation.
Changes in mitochondria fusion and fission have been
proposed to play an important role in the pathogenesis of
PD. Retromer suppression has been shown to be involved
in both fission and fusion but with contrasting effects
(Figure 3). One study found that VPS35 could control
mitochondrial fusion through its regulation of MUL1
mediated turnover of the GTPase protein mitofusin 2
(MFN2) [79]. MFN2 is essential for mitochondrial
fusion, an important event in controlling mitochondrial
morphology, function and degradation. Suppression of
VPS35 causes an increase in MUL1 expression, which
results in the increased degradation of MFN2 leading to
mitochondrial fragmentation and dysfunction [79].
Interestingly, suppression of MUL1 not only restores
MFN2 levels but also protects against mitochondria
dysfunction and remarkably protects against dopaminer-
gic neuronal loss in vitro and in vivo [79].
In contrast, another study found that retromer suppres-
sion causes mitochondria elongation rather than fragmen-
tation which they suggest is due to a decrease in mito-
chondrial fission rather than an alteration in fusion [80].
Dynamin-like protein (DLP1), a cytosolic mitochondrial
fission protein, translocates to the mitochondrial outer
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membrane and forms a large complex to divide mitochon-
dria. However, the mitochondrial DLP1 complex remains
with daughter mitochondria and becomes inhibitory to
the subsequent fission. Overexpression of VPS35 or the
VPS35(p.D620N) mutation displays an enhanced
interaction with the mitochondrial DLP1 complex and
promotes the retromer-dependent turnover of fission-
inhibitory mitochondrial DLP1 complexes via
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Retromer and mitochondrial fusion and fission.
Retromer dysfunction is thought to prevent the degradation of mitochondrial cargo as well as disrupt the balance of mitochondrial fusion/fission
leading to neurodegeneration. Retromer has been shown to interact with the mitochondrial E3 ubiquitin protein ligase 1 (MUL1). MUL1 is enriched
in mitochondria-derived vesicles and is also involved in mitochondrial fusion through it regulation of the mitochondrial protein mitofusin 2 (MFN2).
Retromer suppression causes an increase in MUL1 expression, leading to the increased degradation of MFN2 and mitochondrial fragmentation
and dysfunction. In contrast, retromer has also been shown to interact with the mitochondrial fission protein: dynamin-like protein (DLP1).
Overexpression of retromer or expression of the VPS35(p.D620N) mutation enhances the interaction of retromer with DLP1. This results in the
removal of the DLP-1 complex by mitochondria-derived vesicles for degradation by the lysosome/peroxisome resulting in excessive fission.
Current Opinion in Cell Biology 2017, 47:72–82 www.sciencedirect.com
mitochondria-derived vesicle-dependent trafficking and
lysosomal degradation [80]. Recently the retromer-sort-
ing sequence in DLP1 has been identified and a short
peptide that interrupts the VPS35-DLP1 interaction has
been demonstrated to alleviate VPS35(p.D620N)
mutation-induced mitochondrial fragmentation and
dysfunction [81].
Interestingly MUL1 has also been shown to SUMOylate
and stabilise DLP-1 oligomers at the mitochondria sug-
gesting that retromer may have an important role in the
balance of mitochondrial fusion versus fission, which is
known to determine mitochondrial health [82]. More-
over, retromer may play an important role in the traf-
ficking of cargo from the mitochondria to the peroxi-
some/lysosome for degradation, the impairment of
which, may also contribute to neurodegeneration (Fig-
ure 3) [78]. The precise mechanism by which retromer
may be affecting mitochondria however, is currently
unclear and more research will be needed to fully
understand how retromer dysfunction may be affecting
mitochondrial health.
The PD associated genes Pink1 and Parkin have also
been shown to be involved in the formation and traffick-
ing of mitochondria-derived vesicles and have been
shown to regulate MFN2 and DLP1 ubiquitination
and degradation thereby also affecting mitochondrial
fusion and fission [58,83,84]. Interestingly, VPS35 and
Parkin appear to interact genetically as double mutant
heterozygote flies (vps35MH20/E42/+; park25/+) have an
increased loss of dopaminergic neurons, increased motor
impairment and an increased sensitivity to neurotoxins
[85]. The interface between retromer and mitochondrial
quality control is an interesting and unexpected observa-
tion that in the broader context raises many interesting
questions relating to the connectivity and communication
between endosomal cargo sorting and mitochondrial
function (Figures 2 and 3).
Conclusion
As changes in protein trafficking and degradation are
becoming a major focus in the pathology PD, drug targets
within the retromer complex and its functional pathways
are currently being explored for therapeutic potential
[86]. The recent structural characterization of the retro-
mer complex structure will help aid this targeted drug
design [87]. Future research will need to further expand
our basic understanding of the assembly and function of
this complex, while exploring in more precise detail the in
vivo role of retromer in the maintenance and remodelling
of lysosomal health, remodelling of the functional cell
surface proteome, and more broadly the role of this
protein complex in general proteostasis. Such research
is certain to reveal new and exciting insight into neuronal
health and disease.
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